{"filings":[{"id":91867,"accession_number":"0001140361-26-016424","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AngioDynamics files patent infringement suit against Endovascular Engineering over Hēlo Thrombectomy System","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed patent infringement lawsuit against Endovascular Engineering on April 23, 2026 in Delaware District Court.","Alleges E2's Hēlo Thrombectomy System infringes patents on self-expanding funnel technology for thrombus removal.","Complaint seeks damages and equitable relief for unauthorized use of AngioDynamics' protected features.","AngioDynamics states vigorous IP protection supports continued innovation and improved patient care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91866,"accession_number":"0001140361-26-012891","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.","GAAP net loss $8.1M (-$0.19/shr); adjusted EBITDA $1.8M vs $1.3M prior year.","Raised FY2026 net sales guidance to $313.5-315.5M; adjusted EBITDA now $10-12M (prev $8-10M).","Tariff impact $1.3M in Q3; full-year tariff expectation unchanged at $4-6M.","Cash $37.8M, debt-free; expects Q4 cash flow slightly negative due to $3-5M inventory build for sterilization shutdowns."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":233567000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102257,"accession_number":"0001140361-26-003518","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO James C. Clemmer to retire by Nov 30, 2026; retention awards for NEOs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Clemmer will step down as CEO upon successor appointment or Nov 30, 2026; may extend month-to-month; to serve as consultant for one year.","Equity awards to accelerate vesting at Separation of Service Date; performance-based RSUs remain eligible to vest.","Retention awards: CFO Stephen Trowbridge and three other NEOs get 150% base salary; Lawrence Weiss gets 50%.","Retention conditions: remain employed until 6 months after new CEO starts or June 1, 2027.","Non-compete extended to 24 months; Clemmer releases all claims in exchange for transition benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102256,"accession_number":"0001140361-26-001154","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics CEO presents at J.P. Morgan conference; slide content not disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["President & CEO Jim Clemmer presented at J.P. Morgan 44th Annual Healthcare Conference on Jan 14, 2026.","Presentation slides furnished as Exhibit 99.1 but not reproduced in the filing; specific details unavailable.","No financial results, guidance changes, or material events contained in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102255,"accession_number":"0001140361-26-000341","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.","Raised FY26 net sales guidance to $312-314M (from $308-313M); Adj. EBITDA raised to $8-10M (from $6-10M).","CEO Jim Clemmer to retire in FY2027; board initiates search; Q2 generated $4.7M cash, debt-free balance sheet.","FDA IDE approvals for APEX-Return (AlphaVac blood management) and PAVE (AngioVac right-sided endocarditis) studies.","Federal Circuit affirmed Bard patent invalidation, eliminating $3M contingent payment obligation from prior settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":155144000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118552,"accession_number":"0001140361-25-041542","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AngioDynamics shareholders elect two Class I directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["James C. Clemmer and Michael E. Tarnoff, MD elected as Class I directors with ~29.6M and ~29.2M votes for.","Ratification of Deloitte & Touche as independent auditor for FY2026 approved: 35.7M for, 156.9K against.","Advisory vote on executive compensation approved: 28.4M for, 2.1M against, with 5.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118551,"accession_number":"0001140361-25-037060","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.","Med Tech segment $35.3M (+26.1%): Auryon +20.1%, thrombectomy +41.2%, NanoKnife +26.7%.","Adjusted EBITDA $2.2M vs ($0.2M) prior year; cash $38.8M, debt-free.","Raised FY2026 guidance: net sales $308-$313M, adj EBITDA $6-$10M, adj EPS ($0.33)-($0.23).","Enrolled first patients in AMBITION BTK and RECOVER-AV trials; PRESERVE study published."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":75711000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135028,"accession_number":"0001140361-25-025835","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.","Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.","Cash balance $55.9M; entered $25M revolving credit facility with J.P. Morgan.","Received CPT Category I code for NanoKnife IRE for pancreatic lesions, effective Jan 2027.","FY2026 guidance: net sales $305-310M; pro forma adjusted EBITDA $3-8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":292498000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151978,"accession_number":"0001140361-25-020621","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AngioDynamics enters $25M secured revolving credit facility with JPMorgan Chase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Secured $25 million revolving credit facility from JPMorgan Chase, maturing May 28, 2027.","Borrowing base based on working capital assets; initially subject to $5M availability block until fixed charge coverage ratio >1.10:1.00.","Interest: Term SOFR + 2.00% or ABR + 1.00%, commitment fee 0.20% on unused portion.","Proceeds for general corporate needs and working capital, including during manufacturing transfer.","Company states it remains well capitalized with cash on hand; facility provides incremental flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151977,"accession_number":"0001140361-25-011779","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics hosts virtual Cardiovascular Investor Event on April 2, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Event presentation slides furnished as Exhibit 99.1, but no specific financial or operational updates disclosed in filing.","Company focuses on cardiovascular technologies; no material new data or guidance provided.","Forward-looking statements caution about risks including competition, regulatory approvals, and economic conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151976,"accession_number":"0001140361-25-011767","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.","GAAP net loss $4.4M ($0.11 loss per share); adjusted loss $0.08 per share; adjusted EBITDA $1.3M vs -$3.6M a year ago.","FY2025 guidance raised: net sales $285-288M, Med Tech growth 14-16%, gross margin 53-54%, adjusted EBITDA $4-5M, adjusted EPS loss $(0.31)-(0.34).","Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation; initiated AMBITION BTK RCT for Auryon.","Secured $25M revolver commitment from J.P. Morgan for working capital flexibility; expects positive operating cash flow in Q4."],"consensus_eps_estimate":-0.1199,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":212340000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170817,"accession_number":"0001140361-25-001285","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics CEO presents at J.P. Morgan conference; no material financial updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["James Clemmer, President & CEO, presented at J.P. Morgan 43rd Annual Healthcare Conference on Jan 16, 2025.","Exhibit 99.1 contains only slide title page; no specific financial data, guidance, or operational updates provided.","No material new information disclosed; presentation appears routine investor relations activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170816,"accession_number":"0001140361-25-000538","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AngioDynamics hosts NanoKnife IRE Prostate event; no material financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual investor event on NanoKnife IRE for prostate held January 8, 2025.","Presentation slides provided but contain no new financial results or guidance.","Forward-looking statements caution about competition, regulatory, and clinical risks.","No changes to business outlook or material developments disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170815,"accession_number":"0001140361-25-000535","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).","GAAP net loss $10.7M ($0.26 loss/share); adjusted loss $0.04/share vs $0.08 loss prior year.","Adjusted EBITDA $3.1M (vs $0.0M); FY25 guidance raised to $1-3M from loss of $2.5M-$0; adjusted loss per share guidance improved to $0.34-0.38.","Received FDA 510(k) clearance for NanoKnife prostate tissue ablation and CPT Category I codes for IRE (effective Jan 2026).","Cash $54.1M; operating cash flow $2.5M; $1.1M used on share repurchases in Q2."],"consensus_eps_estimate":-0.1224,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":140336000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187785,"accession_number":"0001140361-24-047071","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AngioDynamics shareholders approve all proposals at 2024 annual meeting including equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class III directors: Burgess, Johnson, Licitra each with >24.8M votes for, 5.99M broker non-votes.","Ratified Deloitte & Touche as FY2025 auditor with 34.1M for, 155k against, 16.5k abstain.","Advisory approval of exec compensation: 26.0M for, 1.25M against, 1.04M abstain, 5.99M broker non-votes.","Approved amended 2020 Equity Incentive Plan increasing share reserve: 23.2M for, 5.06M against, 35k abstain, 5.99M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187784,"accession_number":"0001140361-24-042652","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).","Med Device segment sales $39.5M (-3.6% YoY); U.S. Med Device grew 2.1%.","GAAP net loss $12.8M ($0.31 loss/share); adjusted net loss $4.4M ($0.11 loss/share).","Submitted NanoKnife PRESERVE study to FDA for 510(k) prostate tissue indication; received CE Mark for Auryon in Europe.","FY2025 guidance reaffirmed: net sales $282-288M, adj. EBITDA loss $2.5M-$0, adj. EPS loss $0.38-$0.42."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":67491000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204289,"accession_number":"0001140361-24-033242","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.","GAAP net loss per share $0.33; adjusted loss per share $0.05, improving from $0.11 loss a year ago.","FY2025 guidance: net sales $282-288M, Med Tech growth 10-12%, Med Device growth 1-3%, adjusted EPS loss $0.38-0.42.","Board authorized $15M share repurchase program; no long-term debt, $76.1M cash at May 31, 2024.","Received FDA clearance and CE Mark for AlphaVac F18 in pulmonary embolism; settled decade-long IP litigation with BD/Bard."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":303914000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204288,"accession_number":"0001140361-24-033240","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.","Pro forma adjusted net loss improved to $6.5M ($0.16 loss per share) from $5.4M ($0.14 loss) in Feb 2023.","Pro forma net sales for continuing ops were $66.0M, down 6.9% as reported but up 8.0% constant currency vs prior year.","Med Tech segment pro forma sales grew 13.0% to $25.7M; Med Device segment pro forma sales down 14.7% as reported.","Pro forma adjusted EBITDA loss narrowed to $3.6M from $1.5M in the year-ago quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":303914000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221043,"accession_number":"0001140361-24-017807","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.","Pro forma gross margin 51.1% (-290bps); adj. loss per share $(0.16); adj. EBITDA -$3.6M.","Med Tech sales $25.7M (+12.6%); NanoKnife +46.7%, Auryon +14.7%. Med Device sales $40.3M (+5.2%).","Subsequent events: settled BD/Bard patent litigation; received FDA 510(k) clearance for AlphaVac in pulmonary embolism.","FY2024 guidance lowered: net sales $270-275M (prior $320-325M) due to divestiture/discontinuations; adj. loss per share $(0.54)-(0.58)."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":232934000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221042,"accession_number":"0001140361-24-016977","cik":1275187,"company_name":"ANGIODYNAMICS INC","ticker":"ANGO","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"AngioDynamics settles patent litigation with BD; $7M upfront, $2.5M annual minimums","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time payment of $7M to BD, with $3M due within 5 business days and remainder over 12 months.","Minimum annual payments of $2.5M for six years through Feb 2029; additional payments based on 6% of port product net sales.","Contingent $3M payment due if Federal Circuit reverses invalidity findings in pending appeal (CAFC No. 23-2056).","Cross-licenses granted: BD licenses certain port patents to AngioDynamics; AngioDynamics licenses certain catheter patents.","Mutual covenants not to sue and releases; no admission of misconduct or liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":497892901.73141897,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}